<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="152988">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01845090</url>
  </required_header>
  <id_info>
    <org_study_id>SMHLANFGF23</org_study_id>
    <nct_id>NCT01845090</nct_id>
  </id_info>
  <brief_title>The Effect of Lanthanum Carbonate on Fibroblast Growth Factor 23</brief_title>
  <official_title>Compared the Effect of Lanthanum Carbonate on Fibroblast Growth Factor 23 With Calcium Carbonate in Hemodialysis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Camillians Saint Mary's Hospital Luodong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Camillians Saint Mary's Hospital Luodong</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Taiwan: Department of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare  the effect of lanthanum carbonate with calcium carbonate on serum FGF23 levels
      in hemodialysis patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators enrolled patients on maintenance hemodialysis and randomized them to two
      groups. One group will receive lanthanum carbonate and another group will receive calcium
      carbonate. The investigators will compare serum FGF23 levels between two groups after they
      receive above medication for 6 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>serum level of fibroblast growth factor</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Other Nonspecific Abnormal Serum Enzyme Levels</condition>
  <arm_group>
    <arm_group_label>Lanthanum carbonate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lanthanum carbonate 375mg~750 mg tid for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Calcium carbonate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Calcium carbonate 500mg~1000 mg tid for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lanthanum carbonate</intervention_name>
    <description>the effect on serum FGF23</description>
    <arm_group_label>Lanthanum carbonate</arm_group_label>
    <other_name>Fosrenol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Calcium Carbonate</intervention_name>
    <description>Calcium carbonate 500mg~1000 mg tid for 6 months</description>
    <arm_group_label>Calcium carbonate</arm_group_label>
    <other_name>TOP-CAL(CaCO3)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years old

          -  Chronic renal failure on maintenance hemodialysis 3 times a week for at least 3
             months  Serum calcium:8-10.5 mg/dL

          -  Serum phosphate:3.5-6 mg/dL(before washout period)

          -  Serum phosphate â‰§6 mg/dL after washout period

          -  Serum i-PTH: 150-600 pg/mL

        Exclusion Criteria:

          -  Diabetes mellitus

          -  Post parathyroidectomy

          -  Life expectancy&lt; 6 months

          -  Liver disease(hepatitis B,C or liver dysfunction)

          -  Severe gastrointestinal disorders or other severe comorbidity

          -  Poor compliance

          -  Intolerance to lanthanum or calcium carbonate

          -  Active infection

          -  Malnutrition(serum albumin&lt;3 g/dL or clinical assessment)

          -  Kt/V&lt; 1.2 (inadequate dialysis)

          -  Serum phosphate&gt;7.5 mg/dL after washout period
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shih-Ching Tsai, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saint Mary's hospital-Lotung</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yu-Ming Chang, MD</last_name>
    <email>ynk123.tw@yahoo.com.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>Saint Mary's hospital-Lotung</name>
      <address>
        <city>Taipei</city>
        <zip>265</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu-Ming Chang, MD</last_name>
      <email>ynk123.tw@yahoo.com.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <lastchanged_date>May 1, 2013</lastchanged_date>
  <firstreceived_date>April 24, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Calcium Carbonate</mesh_term>
    <mesh_term>Mitogens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
